INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Brokerages

INmune Bio, Inc. (NASDAQ:INMB) has been assigned an average recommendation of “Buy” from the six research firms that are presently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $22.80.

Several research firms recently commented on INMB. Alliance Global Partners assumed coverage on INmune Bio in a research note on Monday, October 21st. They set a “buy” rating and a $20.00 target price for the company. Scotiabank upped their price objective on INmune Bio from $22.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Tuesday, February 11th. Rodman & Renshaw started coverage on INmune Bio in a research note on Tuesday, January 28th. They set a “buy” rating and a $23.00 target price for the company. Maxim Group increased their target price on INmune Bio from $22.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, RODMAN&RENSHAW raised INmune Bio to a “strong-buy” rating in a research note on Tuesday, January 28th.

Institutional Trading of INmune Bio

Hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC boosted its position in shares of INmune Bio by 601.9% during the third quarter. Barclays PLC now owns 29,044 shares of the company’s stock worth $157,000 after buying an additional 24,906 shares during the period. Jane Street Group LLC bought a new position in shares of INmune Bio in the third quarter valued at $79,000. Geode Capital Management LLC increased its holdings in shares of INmune Bio by 6.6% in the third quarter. Geode Capital Management LLC now owns 344,466 shares of the company’s stock valued at $1,857,000 after buying an additional 21,262 shares in the last quarter. State Street Corp increased its holdings in shares of INmune Bio by 35.1% in the third quarter. State Street Corp now owns 226,428 shares of the company’s stock valued at $1,220,000 after buying an additional 58,838 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new position in shares of INmune Bio in the third quarter valued at $113,000. 12.72% of the stock is owned by hedge funds and other institutional investors.

INmune Bio Trading Down 1.3 %

NASDAQ INMB opened at $9.18 on Thursday. The stock has a market cap of $203.52 million, a PE ratio of -4.21 and a beta of 1.87. INmune Bio has a 12 month low of $4.32 and a 12 month high of $14.49. The stock’s 50 day moving average is $6.61 and its 200 day moving average is $6.12.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.